References: Alopecia AreatA

  1. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology. 2018 Mar-Apr;10(2):51-60. https://www.ncbi.nlm.nih.gov/pubmed/29769777

  2. Trüeb RM, Dias MFRG. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. Clin Rev Allergy Immunol. 2018 Feb;54(1):68-87. https://www.ncbi.nlm.nih.gov/pubmed/28717940

  3. Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester epidemiology project, 1990-2009. J Invest Dermatol. 2014;134:1141–2

  4. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. (1995) Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70(7):628–633

  5. Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis.  Br J Dermatol. 2018 May 23. 

  6. Lee S, Lee H, Lee CH, Lee WS.  Comorbidities in alopecia areata: A systematic review and meta-analysis.  J Am Acad Dermatol. 2018 Jul 18. pii: S0190-9622(18)32285-0.

  7. Kaplan L, Castelo-Soccio L. When your patient's parent asks: "My child's alopecia areata is not getting better. Should he or she get tested for celiac disease?"Pediatr Dermatol. 2018 Jul;35(4):535-538.   

  8. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438–41. 

  9. Phan K, Ramachandran V, Sebaratnam DF.  Methotrexate for alopecia areata: a systematic review and meta-analysis.  J Am Acad Dermatol. 2018 Jul 9. pii: S0190-9622(18)32223-0.

  10. Park J, Kim DW, Park SK, Yun SK, Kim HU. Role of Hair Prostheses (Wigs) in Patients with Severe Alopecia Areata. Ann Dermatol. 2018 Aug;30(4):505-507.

  11. Park H, Kim CW, Kim SS, Park CW. The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. Ann Dermatol. 2009;21(2):142-146.

  12. Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018 Aug 30

  13. Cheng MW, Kehl A, Worswick S, Goh C. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.  J Drugs Dermatol. 2018 Jul 1;17(7):800-803.

  14. Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata.  J Am Acad Dermatol. 2018 Sep 6. pii: S0190-9622(18)32494-0. 

  15. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169:690–4.

  16. El Taieb MA, Ibrahim H, Nada EA, Seif Al-Din M. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation. Dermatologic therapy. 2017;30(1)

  17. Hay, I.C., Jamieson, M., Ormerod, A.D., 1998. Randomized trial of aromatherapy: successful treatment of alopecia areata. Arch. Dermatol. 134, 1349–1352.

  18. Thompson JM, Park MK, Qureshi AA, Cho E.  Race and Alopecia Areata amongst US Women J Investig Dermatol Symp Proc. 2018 Jan;19(1):S47-S50.